covid
Buscar en
Angiología
Toda la web
Inicio Angiología Estudio de las repercusiones clínicas y analíticas de una intervención nutric...
Información de la revista
Vol. 58. Núm. 1.
Páginas 19-30 (enero 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 58. Núm. 1.
Páginas 19-30 (enero 2005)
Acceso a texto completo
Estudio de las repercusiones clínicas y analíticas de una intervención nutricional en pacientes no hospitalizados con claudicación intermitente. Estudio aleatorio controlado
A study of the clinical and analytical repercussions of a nutritional intervention in non-hospitalised patients with intermittent claudication. A controlled randomised study
Visitas
2486
J.J. Carreroa, L.M. Salmerón-Febresb,
Autor para correspondencia
lmsalmeron@yahoo.es

Correspondencia: Servicio de Angiología y Cirugía Vascular. Hospital Clínico San Cecilio. Avda. Doctor Oloriz, 12. E-18012 Granada.
, V.E. Ramos-Gutiérrezb, E. López-Huertasc, E. Ros-Díeb
a Departamento de Bioquímica y Biología Molecular. Universidad de Granada
b Servicio de Angiología y Cirugía Vascular. Hospital Clínico San Cecilio
c Departamento de Nutrición y Salud. Puleva Biotech. Granada, España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Introducción

La dieta es un pilar fundamental, a veces olvidado, en el control y tratamiento de la enfermedad vascular periférica (EVP).

Objetivo

Estudiar los efectos de la ingesta de ciertos nutrientes con probado efecto beneficioso en la prevención de la enfermedad coronaria en la clínica y el perfil bioquímico de enfermos claudicantes.

Pacientes y métodos

Estudio longitudinal, descriptivo, aleatorio y doble ciego, con 60 varones claudicantes (grado IIB de Fontaine), distribuidos en dos grupos. Grupo I (n = 30): además de su dieta habitual consumieron 500mL/día de leche semidesnata-da adicionada de ácidos eicosapentanoico, docoxahexanoico, oleico y fólico y vitaminas A, D, Ey B6. Grupo C (n = 26): además de su dieta habitual consumieron 500mL/día de leche semidesnatada. Ambos grupos obtuvieron los mismos consejos higienicodietéticos, un antiagreganteplaquetario (triflusal) y un hemorreológico (pentoxifilina). Con control trimestral, la intervención duró 12 meses. En cada control se realizó una exploración clínica vascular, claudicometría, índice de Yao, placetismografía y analítica.

Resultados

La concentración plasmática de los nutrientes suministrados aumentó en el grupo I (p < 0,05), seguido de un descenso en colesterol total y la concentración de apolipoproteína B. La homocisteína total disminuyó en aquellos pacientes con hiperhomocisteinemia (p < 0,01). Paralelamente, la distancia de claudicación triplicó su valor (p < 0,001) y el índice de Yao aumentó de manera gradual (p < 0,05).

Conclusiones

La inclusión diaria en la dieta de ciertos nutrientes cardiosaludables produjo, junto con otras recomendaciones dietéticas y hábitos de vida, una mejora significativa en los parámetros clínicos y analíticos de este grupo de claudicantes. La nutrición puede desempeñar un papel importante en el tratamiento y control de la EVP. [ANGIOLOGÍA 2006; 58: 19-30]

Palabras clave:
Ácido fólico
Ácido oleico
Ácidos grasos omega 3
Enfermedad vascular periférica
Vitamina B6
Vitamina E
Summary
Introduction

Diet is a sometimes neglected cornerstone in the control and treatment of peripheral vascular disease (PVD).

Aims

To study how the intake of certain nutrients with a proven beneficial effect in the prevention of heart disease affects the clinical symptoms and biochemical profile of patients with claudication.

Patients and methods

A longitudinal, descriptive, randomised, double-blind study was conducted with 60 males with claudication (Fontaine grade IIB), distributed in two groups. Group I (n = 30): in addition to their usual diet, subjects consumed 500ml/day of semi-skimmed milk with added eicosapentaenoic, docosahexaenoic, oleic and folic acids, as well as vitamins A, D, E and B6. Group C (n = 26): in addition to their usual diet, subjects consumed 500mL/day of semi-skimmed milk. Both groups received the same hygienic-dietary guidelines, an antiplatelet drug (triflusal) and a haemorrheologic agent (pentoxifylline). Including a three-monthly control, the intervention lasted 12 months. At each control the following tests were carried out: vascular clinical examination, treadmill exercise testing, Yao index, plethysmography and analyses.

Results

The plasma concentration of the nutrients given to patients increased in group I (p < 0.05), followed by a decrease in total cholesterol and apolipoprotein B concentration. The total homocysteine level dropped in patients with hyperhomocysteinemia (p < 0.01). In a parallel fashion, the claudication distance become three times longer (p < 0.001) and the Yao index gradually increased (p < 0.05).

Conclusions

Including certain nutrients that are good for the heart in the daily diet, along with other guidelines concerning nutrition and lifestyle, led to a significant improvement in the clinical and analytical parameters of this group of patients with claudication. Nutrition can play an important role in the treatment and control of PVD. [ANGIOLOGÍA 2006; 58: 19-30]

Key words:
Folic acid
Oleic acid
Omega-3 fatty acids
Peripheral vascular disease
Vitamin B6
Vitamin E
El Texto completo está disponible en PDF
Bibliografía
[1.]
Henke P.K., Blackburn S., Proctor M.C., Stevens J., Mukherjee D., Rajagopalin S., et al.
Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality.
J Vasc Surg, 39 (2004), pp. 357-365
[2.]
Cassar K., Coull R., Bachoo P., Macaulay E., Brittenden J..
Management of secondary risk factors in patients with intermittent claudication.
Eur J Vasc Endovasc Surg, 26 (2001), pp. 262-266
[3.]
Mukherjee D., Lingam P., Chetcuti S., Grossman P.M., Moscucci M., Luciano A.E., et al.
Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVDQI2).
Circulation, 106 (2002), pp. 1909-1912
[4.]
Hirsch A.T., Hiatt W.R., PARTNERS Steering Committee.
PAD awareness, risk, and treatment: new resources for survival: the USA PARTNERS program.
Vasc Med, 6 (2001), pp. 9-12
[5.]
Regensteiner J.G., Hiatt W.R..
Current medical therapies for patients with peripheral arterial disease: a critical review.
Am J Med, 112 (2002), pp. 49-57
[6.]
Hiatt W.R..
Peripheral arterial disease detection, awareness, and treatment in primary care.
JAMA, 286 (2001), pp. 1317-1324
[7.]
Leng G.C., Fowkes F.G.R..
The epidemiology of peripheral arterial disease.
Vasc Med Rev, 4 (1993), pp. 5-18
[8.]
Muluk S.C., Muluk V.S., Kelley M.E., Whittle J.C., Tierney J.A., Webster M.W., et al.
Outcome events in patients with claudication: a 15-years study in 2777 patients.
J Vasc Surg, 33 (2001), pp. 251-257
[9.]
TransAtlantic Inter-Society Consensus (TASC) Working Group.
Management of peripheral arterial disease.
J Vasc Surg, 31 (2001), pp. 5-14
[10.]
Ouriel K..
Peripheral arterial disease.
Lancet, 358 (2001), pp. 1257-1264
[11.]
Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al.
Mortality over a period of 10 years in patients with peripheral arterial disease.
N Engl J Med, 326 (1992), pp. 381-386
[12.]
Vogt M.T., Wolfson S.K., Kuller L.H..
Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality.
J Clin Epidemiol, 46 (1993), pp. 1267-1276
[13.]
Leng G.C., Fowkes F.G., Lee A.J., Dunbar J., Housley E., Ruckley C.V..
Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.
BMJ, 313 (1996), pp. 1440-1444
[14.]
Brevetti G., Chiariello M., Ferulano G., Policicchio A., Nevola E., Rossini A., et al.
Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
Circulation, 77 (1998), pp. 767-773
[15.]
WHO Study Group.
Diet, nutrition and prevention of chronic diseases.
Technical Report Series, 916 (2003),
[16.]
Spark J.I., Robinson J.M., Gallavin L., Gough M.J., Homer-Vanniasinkam S., Kester R.C., et al.
Patients with chronic critical limb ischemia have reduced total antioxidant capacity and impaired nutritional status.
Eur J Vasc Endovasc Surg, 24 (2002), pp. 535-539
[17.]
Sommerfield T., Hiatt W.R..
Omega-3 fatty acids for intermittent claudication (Cochrane review). The Cochrane Library, Issue 3, John Wiley & Sons, (2004),
[18.]
Ramírez-Tortosa M.C., Urbano G., López-Jurado M., Nestares T., Gómez M.C., Mir A., et al.
Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in free-living men with peripheral vascular disease.
J Nutr, 129 (1999), pp. 2177-2183
[19.]
Aguilera C.M., Mesa M.D., Ramírez-Tortosa M.C., Nestares M.T., Ros E., Gil A..
Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease.
Clin Nutr, 23 (2004), pp. 673-681
[20.]
Kleijnen J., Mackerras D..
Vitamin E for intermittent claudication (Cochrane review). The Cochrane Library, Issue 3, John Wiley & Sons, (2004),
[21.]
Robinson K., Arheart K., Refsum H., Brattstrom L., Boers G., Ueland P., et al.
Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group.
Circulation, 97 (1998), pp. 437-443
[22.]
Wilmink A.B., Welch A.A., Quick C.R., Burns P.J., Hubbard C.S., Bradbury A.W., et al.
Dietary folate and vitamin B6 are independent predictors of peripheral arterial occlusive disease.
J Vasc Surg, 39 (2004), pp. 513-516
[23.]
Hooper L., Griffiths E., Abrahams B., Alexander W., Atkins S., Atkinson G., et al.
Dietetic guidelines: diet in secondary prevention of cardiovascular disease (first update, june 2003).
J Hum Nutr Diet, 17 (2004), pp. 337-349
[24.]
Third Report of the National Cholesterol Education Programme Expert Panel on ‘Detection, evaluation and treatment of high blood cholesterol in adults (ATP III)'. National Institutes of Health (NIH), núm. 02-5215; 2002.
[25.]
Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E..
Plasma homocysteine levels and mortality in patients with coronary artery disease.
N Engl J Med, 337 (1997), pp. 230-236
[26.]
Visioli F., Rise P., Plasmati E., Pazzucconi F., Sirtori C., Galli C..
Very low intakes of n-3 fatty acids incorporated into bovine milk reduce plasma triacylglycerols and increase HDL-cholesterol concentrations in healthy subjects.
Pharmacol Res, 41 (2000), pp. 571-576
[27.]
Baro L., Fonolla J., Pena J.L., Martínez-Ferez A., Lucena A., Jímenez J., et al.
n-3 fatty acids plus oleic acid and vitamin supplemented milk consumption reduces total and LDL cholesterol, homocysteine and levels of endothelial adhesion molecules in healthy humans.
Clin Nutr, 22 (2003), pp. 175-182
[28.]
Carrero J.J., Baro L., Fonolla J., Gónzalez-Santiago M., Martínez-Ferez A., Castillo R., et al.
Cardiovascular effects of milk enriched with omega-3 polyunsaturated fatty acids, oleic acid, folic acid, and vitamins E and B6 in volunteers with mild hyperlipidemia.
Nutrition, 20 (2004), pp. 521-527
[29.]
Calder P.C..
N-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored.
Clin Sci (Lond), 107 (2004), pp. 1-11
[30.]
Singleton C.B., Walker B.D., Campbell T.J..
N-3 polyunsaturated fatty acids and cardiac mortality.
Aust N Z J Med, 30 (2000), pp. 246-251
[31.]
Ernst E..
Effects of n-3 fatty acids on blood rheology.
J Intern Med, 225 (1989), pp. 129-132
[32.]
Ho M., Maple C., Bancroft A., McLaren M., Belch J.J..
The beneficial effects of omega-3 and omega-6 essential fatty acid supplementation on red blood cell rheology.
Prostaglandins Leukot Essent Fatty Acids, 61 (1999), pp. 13-17
[33.]
Vicaut E..
Opposite effects of red blood cell aggregation on resistance to blood flow.
J Cardiovasc Surg, 36 (1995), pp. 361-368
[34.]
Thies F., Garry J.M., Yaqoob P., Rerkasem K., Williams J., Shearman C.P., et al.
Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.
[35.]
Grundy S.M..
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
Circulation, 106 (2002), pp. 2526-2529
[36.]
Senti M., Nogues X., Pedro-Botet J., Rubies-Prat J., Vidal-Barraquer F..
Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes.
Circulation, 85 (1992), pp. 30-36
[37.]
Garrison R.J., Kannel W.B., Feinleib M., Castelli W.P., McNamara P.M., Padgett S.J..
Cigarette smoking and HDL cholesterol: the Framingham offspring study.
Atherosclerosis, 30 (1978), pp. 17-25
[38.]
Morrissey P.A., Sheehy P.J..
Optimal nutrition: vitamin E.
Proc Nutr Soc, 58 (1999), pp. 459-468
[39.]
Bronstrup A., Hages M., Prinz-Langenohl R., Pietrzik K..
Effects of folic acid and combinations of folic acid and vitamin B12 on plasma homocysteine concentrations in healthy young women.
Am J Clin Nutr, 68 (1998), pp. 1104-1110
[40.]
Taylor L.M. Jr, DeFrang R.D., Harris E.J. Jr, Porter J.M..
The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease.
J Vasc Surg, 13 (1991), pp. 128-136
[41.]
Riba R., Nicolau A., Troxler M., Homer-Vaniasinkam S., Naseem K.M..
Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels.
Atherosclerosis, 175 (2004), pp. 69-75
[42.]
De Vriese A.S., Blom H.J., Heil S.G., Mortier S., Kluijtmans L.A., van de Voorde J., Lameire N.H..
Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia.
Circulation, 109 (2004), pp. 2331-2336
[43.]
Trichopoulou A., Costacou T., Bamia C., Trichopoulos D..
Adherence to a mediterranean diet and survival in a greek population.
N Engl J Med, 348 (2003), pp. 2599-2608
Copyright © 2006. SEACV
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos